About
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 296 million people worldwide.
Patients and caregivers
Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.
Healthcare professionals
Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.
Research & development
Discover how Novartis turns breakthrough science into transformative, high-value treatments.
Environmental, social and governance
Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.
Investors
Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.
News
Information for journalists including media releases, statements, stories, multimedia resources and more.
Careers
Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.
Home
Working together, we can reimagine medicine to improve and extend people’s lives.
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Home Reported Outcomes in C3G Study
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)